2022 guidance for Comirnaty (COVID vaccine) is now $34B (from prior $32B). 2022 guidance of Paxlovid remains $22B.
2022 non-GAAP EPS guidance is now $6.40-6.50 (from the prior range of $6.30-6.45), despite an increased headwind from currency exchange rates (i.e. the strong US dollar).
Market Data 
Markets 
AI
